Index - P/E - EPS (ttm) - Insider Own 53.70% Shs Outstand 31.85M Perf Week -3.34%
Market Cap 728.09M Forward P/E - EPS next Y - Insider Trans 98.80% Shs Float 14.75M Perf Month -
Income - PEG - EPS next Q - Inst Own - Short Float - Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio - Perf Half Y -
Book/sh -3.07 P/B - EPS next Y - ROA - Short Interest - Perf Year -
Cash/sh 1.74 P/C 13.18 EPS next 5Y - ROE - 52W Range 20.29 - 26.08 Perf YTD -3.34%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -12.35% Beta -
Dividend TTM - Quick Ratio 7.17 Sales past 5Y 0.00% Gross Margin - 52W Low 12.69% ATR (14) 2.78
Dividend Ex-Date - Current Ratio 7.17 EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility - -
Employees - Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom - Target Price -
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q - Payout - Rel Volume 0.71 Prev Close 21.23
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings - Avg Volume 469.70K Price 22.86
SMA20 4.83% SMA50 4.83% SMA200 4.83% Trades
Volume 203,958 Change 7.68%
Sep-18-24 03:19AM
Sep-16-24 04:05PM
Sep-12-24 07:11PM
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mathers Edward T Director Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:28 PM BASKETT FOREST 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:26 PM Behbahani Ali 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:24 PM Chang Carmen 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:23 PM Florence Anthony A. Jr. 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:21 PM Makhzoumi Mohamad 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:20 PM Walker Paul Edward 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:18 PM Yang Rick 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:17 PM SANDELL SCOTT D 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:14 PM ORBIMED ADVISORS LLC Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:13 PM New Enterprise Associates 17, 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:12 PM Frazier Life Sciences X, L.P. 10% Owner Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:11 PM Heron Patrick J Director Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:09 PM Aynechi Tiba Director Sep 16 '24 Buy 16.00 750,000 12,000,000 2,136,335 Sep 17 08:05 PM GORDON CARL L Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:05 PM
Index RUT P/E - EPS (ttm) -3.39 Insider Own 63.18% Shs Outstand 47.67M Perf Week -0.01%
Market Cap 91.09M Forward P/E - EPS next Y -1.52 Insider Trans -0.16% Shs Float 18.33M Perf Month -8.51%
Income -156.27M PEG - EPS next Q -0.35 Inst Own 46.29% Short Float 10.76% Perf Quarter -86.00%
Sales 0.00M P/S - EPS this Y 12.12% Inst Trans -0.53% Short Ratio 1.77 Perf Half Y -88.47%
Book/sh 4.16 P/B 0.44 EPS next Y 42.94% ROA -55.47% Short Interest 1.97M Perf Year -87.44%
Cash/sh 4.92 P/C 0.37 EPS next 5Y - ROE -73.77% 52W Range 1.55 - 20.22 Perf YTD -88.60%
Dividend Est. - P/FCF - EPS past 5Y -241.80% ROI -68.90% 52W High -90.95% Beta 0.80
Dividend TTM - Quick Ratio 5.14 Sales past 5Y 0.00% Gross Margin - 52W Low 18.05% ATR (14) 0.12
Dividend Ex-Date - Current Ratio 5.14 EPS Y/Y TTM -37.60% Oper. Margin 0.00% RSI (14) 37.12 Volatility 4.57% 5.08%
Employees 90 Debt/Eq 0.25 Sales Y/Y TTM - Profit Margin - Recom 3.00 Target Price 3.33
Option/Short No / Yes LT Debt/Eq 0.11 EPS Q/Q -12.47% Payout - Rel Volume 0.21 Prev Close 1.81
Sales Surprise - EPS Surprise -6.22% Sales Q/Q - Earnings Aug 08 AMC Avg Volume 1.11M Price 1.83
SMA20 0.15% SMA50 1.84% SMA200 -83.94% Trades
Volume 144,379 Change 1.09%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-09-24 Downgrade Stifel
Buy → Hold
$34 → $3
Jul-09-24 Downgrade Leerink Partners
Outperform → Market Perform
$28 → $2
Jul-09-24 Downgrade H.C. Wainwright
Buy → Neutral
$28 → $2
Jul-08-24 Downgrade JP Morgan
Overweight → Neutral
$24 → $5
Jul-08-24 Downgrade Guggenheim
Buy → Neutral
Dec-13-23 Initiated H.C. Wainwright
Buy
$28
Aug-08-24 07:20PM
Aug-01-24 11:53AM
(Pharmaceutical Technology)
Jul-31-24 04:00PM
Jul-29-24 09:35AM
Jul-11-24 09:35AM
10:19AM
Loading…
Jul-09-24 10:19AM
Jul-08-24 12:36PM
12:17PM
08:42AM
08:16AM
07:30AM
May-23-24 02:15AM
May-10-24 02:26PM
May-09-24 11:55PM
04:05PM
12:52PM
Loading…
Apr-14-24 12:52PM
Apr-06-24 01:33AM
Mar-21-24 02:32AM
Mar-20-24 09:53PM
04:00PM
Mar-08-24 11:55PM
Feb-22-24 11:27PM
Feb-05-24 04:05PM
Jan-18-24 07:00AM
Jan-08-24 07:00AM
Jan-03-24 06:28PM
Dec-19-23 01:01PM
Dec-05-23 09:48PM
Nov-30-23 09:55AM
Nov-21-23 11:03AM
12:00PM
Loading…
Nov-14-23 12:00PM
09:55AM
Nov-09-23 04:05PM
Nov-01-23 04:48PM
Sep-26-23 04:01PM
Sep-25-23 07:00AM
Sep-19-23 08:05PM
04:09PM
Aug-24-23 10:40AM
Aug-14-23 05:08PM
(American City Business Journals) -7.26%
-10.17%
07:00AM
Jun-07-23 09:55AM
May-22-23 09:55AM
May-12-23 04:05PM
May-09-23 07:00AM
Apr-25-23 06:45AM
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kohli Aditya Director May 20 '24 Sale 15.45 6,000 92,689 776,878 May 22 05:40 PM Kohli Aditya Director May 22 '24 Sale 14.73 6,000 88,372 764,878 May 22 05:40 PM Kohli Aditya Director May 21 '24 Sale 14.21 6,000 85,230 770,878 May 22 05:40 PM Kohli Aditya Director May 02 '24 Sale 14.01 6,000 84,081 783,601 May 03 07:12 PM Kohli Aditya Director May 03 '24 Sale 14.15 723 10,233 782,878 May 03 07:12 PM Kohli Aditya Director May 01 '24 Sale 14.03 175 2,456 789,601 May 03 07:12 PM Frazier Life Sciences X, L.P. 10% Owner Apr 04 '24 Buy 14.50 8,850 128,325 8,544,187 Apr 08 04:22 PM Kohli Aditya Director Apr 03 '24 Sale 14.93 6,000 89,582 801,776 Apr 05 05:48 PM Kohli Aditya Director Apr 04 '24 Sale 14.71 6,000 88,245 795,776 Apr 05 05:48 PM Kohli Aditya Director Apr 05 '24 Sale 14.44 6,000 86,640 789,776 Apr 05 05:48 PM McLoughlin Sean Chief Operating Officer Mar 28 '24 Buy 16.98 1,250 21,225 1,250 Apr 01 04:08 PM Kohli Aditya Director Mar 18 '24 Sale 17.66 6,000 105,937 819,776 Mar 20 06:27 PM Kohli Aditya Director Mar 19 '24 Sale 17.42 6,000 104,492 813,776 Mar 20 06:27 PM Kohli Aditya Director Mar 20 '24 Sale 16.42 6,000 98,533 807,776 Mar 20 06:27 PM Kohli Aditya Director Mar 06 '24 Sale 18.95 6,000 113,701 837,776 Mar 08 06:38 PM Kohli Aditya Director Mar 08 '24 Sale 18.66 6,000 111,959 825,776 Mar 08 06:38 PM Kohli Aditya Director Mar 07 '24 Sale 18.37 6,000 110,213 831,776 Mar 08 06:38 PM Kohli Aditya Director Feb 22 '24 Sale 15.05 6,000 90,312 843,776 Feb 22 05:20 PM Kohli Aditya Director Feb 21 '24 Sale 14.92 6,000 89,495 849,776 Feb 22 05:20 PM Kohli Aditya Director Feb 20 '24 Sale 14.88 6,000 89,272 855,776 Feb 22 05:20 PM Kohli Aditya Director Feb 12 '24 Sale 15.32 6,000 91,921 861,776 Feb 14 04:22 PM Kohli Aditya Director Feb 08 '24 Sale 14.93 8,866 132,383 812,878 Feb 12 08:06 PM Maltbie Shane Chief Financial Officer Feb 08 '24 Sale 14.93 3,576 53,395 40,656 Feb 12 07:51 PM HERSHBERG ROBERT See Remarks Feb 08 '24 Sale 14.93 11,597 173,161 953,831 Feb 12 07:47 PM Borkowski Astrid Chief Medical Officer Feb 08 '24 Sale 14.93 3,933 58,726 161,260 Feb 12 07:35 PM Borkowski Astrid Chief Medical Officer Dec 15 '23 Sale 15.50 10,000 155,000 165,193 Dec 18 05:34 PM Borkowski Astrid Chief Medical Officer Dec 04 '23 Sale 14.50 10,000 145,000 175,193 Dec 05 04:52 PM Borkowski Astrid Chief Medical Officer Dec 01 '23 Sale 14.20 10,000 142,000 185,193 Dec 05 04:52 PM Borkowski Astrid Chief Medical Officer Nov 17 '23 Sale 14.00 10,000 140,000 195,193 Nov 20 04:53 PM Borkowski Astrid Chief Medical Officer Nov 08 '23 Sale 13.00 5,000 65,000 205,193 Nov 13 05:25 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
